As Poland announces plans to create a British-style NHS, a recent paper has proposed that one priority should be to address the potential blurred boundaries between public bureaucracies, politicians and industry providers such as pharmaceutical companies.
Pharma and Cold Chain IQ explores the varying views and predictions on the potential outcomes which could occur from Brexit.
Traditionally the pharma industry has lent toward the view of adhering to a one-size fits all approach to the application of therapeutics. However, now eyes are set firmly on the notion of personalised medicine – therapeutics tailored to a patient’s specific biomarker information. The progression of next generation sequencing and genome technology is allowing for the first tangible personalised therapies to emerge.
Pharma IQ takes a look at some of the industry’s most prestigious movers and shakers causing ripples in the market over the last few months.
In order to examine the therapy which has been labelled as a game changing addition to oncology, earlier this month industry stakeholders met to explore the evidenced potential of immune checkpoint modulation therapies. The two day conference also saw attendees discuss and formulate tactics to scale the roadblocks encountered by the therapy.
Biomarkers are an essential part of such a translational effort and are critical to understanding human disease. Human biospecimens can provide a bridge between the early discovery and molecular mechanism of the disease and the clinical utility. Commonly, human biospecimens are used to:
The balanced scorecard was first developed as a way for companies and organizations to more accurately measure their own performances. Today, these scorecards have evolved into vital tools for biopharmaceutical organizations to plan, measure, and manage their business strategies.
There are questions virtually everyone in our industry asks when the topic of commercialization inevitably comes up: What is new in molecule commercialization? How do I beat my closest competitor? When do I initiate commercial activities? What can I do based on promotional regulations?
The first quarter of 2016 hosted plenty of activity from the pharma and cold chain industries. This was seen in the form of patent challenges, landmark agreements, extreme market reactions as well as a nationwide medicine ban for hundreds of products. Read on for this quarter’s highlights from Pharma IQ